Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11389
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsang, Benjamin K-Ten
dc.contributor.authorMacdonell, Richard A Len
dc.date.accessioned2015-05-16T00:58:47Z
dc.date.available2015-05-16T00:58:47Z
dc.date.issued2011-12-01en
dc.identifier.citationAustralian Family Physician; 40(12): 948-55en
dc.identifier.govdoc22146321en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11389en
dc.description.abstractMultiple sclerosis is the most common chronic disabling disease of the central nervous system in young adults.This article summarises the diagnosis, management and prognosis of multiple sclerosis.Multiple sclerosis usually starts with an acute episode of neurological disturbance, termed a 'clinically isolated syndrome', followed by an illness phase punctuated by relapses and remissions which may transition after 10 years to a phase of progressive accumulation of disability without relapses. Fifteen to 20% of patients will have a progressive course from the onset. There is significant interpatient variability in prognosis. The main diagnostic criteria are clinical, supported by investigations including magnetic resonance imaging and lumbar puncture and evoked potentials. First line disease modifying agents for relapsing remitting multiple sclerosis include interferon-ß and glatiramer. First line treatment for relapses is usually intravenous methylprednisolone for 3 days. Troublesome symptoms may include spasticity, parasthesias, tremor, erectile dysfunction, depression and anxiety, fatigue and pain. After excluding differential diagnoses, symptomatic management includes pharmacological agents, allied health consultation and continence strategies. Although pregnancy reduces disease activity, there is a higher risk of relapse in the postpartum period.en
dc.language.isoenen
dc.subject.otherAdjuvants, Immunologic.administration & dosageen
dc.subject.otherAdulten
dc.subject.otherAntineoplastic Agents.administration & dosageen
dc.subject.otherAustralia.epidemiologyen
dc.subject.otherDiagnosis, Differentialen
dc.subject.otherDisease Progressionen
dc.subject.otherFamily Practice.statistics & numerical dataen
dc.subject.otherFemaleen
dc.subject.otherHealth Statusen
dc.subject.otherHumansen
dc.subject.otherImmunoglobulins, Intravenous.administration & dosageen
dc.subject.otherImmunologic Factors.administration & dosageen
dc.subject.otherInterferon-beta.administration & dosageen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherMitoxantrone.administration & dosageen
dc.subject.otherMultiple Sclerosis.diagnosis.drug therapy.epidemiologyen
dc.subject.otherPhysician's Practice Patterns.statistics & numerical dataen
dc.subject.otherYoung Adulten
dc.titleMultiple sclerosis- diagnosis, management and prognosis.en
dc.typeJournal Articleen
dc.identifier.journaltitleAustralian Family Physicianen
dc.identifier.affiliationDepartment of Neurology, Austin Hospital, Melbourne, Victoria, Australiaen
dc.description.pages948-55en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/22146321en
dc.type.austinJournal Articleen
local.name.researcherMacdonell, Richard A L
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.